Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medigen Biotechnology's revenue for the
three
months ended in Mar. 2026 was NT$261 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was NT$1,345 Mil.
Medigen Biotechnology's Revenue per Share for the
three
months ended in Mar. 2026 was NT$1.87.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$9.65.
Warning Sign:
Medigen Biotechnology Corp revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Medigen Biotechnology was -15.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 19.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Medigen Biotechnology's highest 3-Year average Revenue per Share Growth Rate was 357.90% per year. The lowest was -42.10% per year. And the median was 12.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Medigen Biotechnology's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Revenue distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,345 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) has a Revenue of NT$1,345 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Revenue too high?
Medigen Biotechnology's current Revenue is NT$1,345 Mil. Overall, Medigen Biotechnology has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Revenue compare to VRTX and REGN?
Medigen Biotechnology's Revenue of NT$1,345 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Revenue is NT$1,345 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Fairly Valued. The stock's GF Value™ is NT$37.04, compared to a current price of NT$34.00 — trading 8.2% below its estimated fair value. The current Revenue is NT$1,345 Mil. Medigen Biotechnology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Revenue is NT$1,345 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$34.00 is trading 8.2% below its estimated GF Value™ of NT$37.04.
GuruFocus considers Medigen Biotechnology to be Fairly Valued.
Key valuation signals for ROCO:3176:
Revenue: NT$1,345 Mil
GF Value™: NT$37.04 vs. price of NT$34.00 (8.2% below fair value)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
55GF Score
Get the complete analysis for ROCO:3176
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
